cancer. Following five weeks of treatment, a patient’s large, stage 4 tumor was
reduced in size by 70%. After seven more weeks of treatment, it no longer could
be definitely identified on scans. Pancreatic cancer usually is fatal six to
nine months after diagnosis. NeoPlas Innovation’s combination of FDA-approved
drugs appears to improve those odds for some patients, based on this result and
similar ones seen before the protocol’s public availability.